Salix Pharmaceuticals is a pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a range of gastrointestinal diseases, which are those affecting the digestive tract. Co.'s products include among others, XIFAXAN550® (rifaximin) Tablets, indicated for the reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years and older; XIFAXAN (rifaximin) tablets, indicated for the treatment of patients 12 years of age and older with travelers' diarrhea; and APRISO® (mesalamine) extended-release capsules, indicated for the maintenance of remission of ulcerative colitis.
|
Free SLXP Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Hold (2.18 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |